![Jack Rubinstein, researcher and professor of internal medicine at UC College of Medicine](https://www.uc.edu/news/articles/2024/03/n21234919/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1710782312909.jpg)
Business Courier: UC researcher pumped about breakthrough for treatment of heart disease
Gout medication discovery emerges as game changer for patients with heart failure
A University of Cincinnati researcher made a groundbreaking discovery that has the potential to revolutionize the treatment of heart failure, as reported by the Cincinnati Business Courier.
Jack Rubinstein, MD, is the chief medical officer launching TRPV Pharmaceuticals, a company dedicated to advancing a therapeutic approach for cardiovascular disease.
Rubinstein is also a UC professor of internal medicine at the UC College of Medicine and a pioneering researcher in the field of cardiovascular diseases.
Through more than a decade of intense research, Rubinstein uncovered a remarkable revelation:
- An FDA-approved medication initially designed for gout management known as probenecid could be repurposed to significantly improve the lives of heart patients grappling with decreased cardiac output or weakened heart contractability, a condition known as heart failure.
Rubinstein shared circumstances under which the heart muscle can fail to pump blood effectively, leading to inadequate circulation.
Partnering with Fred Sexton, a seasoned entrepreneurial pharmaceutical industry executive with experience developing successful startups, the two co-founded TRPV Pharmaceuticals.
Sexton serves as CEO of TRPV Pharmaceuticals and said, “The company's launch centers around advancing treatments based on transient receptor potential vanilloid (TRPV) channel agonists, with its primary focus on probenecid, the substance found in gout medication and the active ingredient in the drug we are currently developing.”
Safety is our No. 1 concern. The drug we are developing aims to improve the way the heart pumps, increase patient survival and enhance overall well-being.
Jack Rubinstein, MD Chief medical officer of TRPV Pharmaceuticals, UC researcher and professor of internal medicine, UC College of Medicine
The products under development at TRPV Pharma will include multiple dosage forms of probenecid to be used during episodes of acute decompensated heart failure.
“So, our whole approach to developing this molecule for commercial purposes is to better serve patients with an acute event of congestive heart failure. When we look more holistically, anything that we can do to help the patient at that point is critically important,” Rubinstein said. “Stabilizing them sooner reduces the individual cost for that patient, and they return home with an oral version to help sustain improved heart contractility.”
Rubinstein said the four existing "pharmacologic pillars" for managing heart failure in patients address different aspects of heart failure, however, none of these enhances contractility.
“Safety is our No. 1 concern,” Rubinstein said. “The drug we are developing aims to improve the way the heart pumps, increase patient survival and enhance overall well-being. Anticipating no adverse effects on cardiac health, our drug promises to be a safe treatment option. We see it as a potential ‘fifth pillar’ to complimenting the existing pharmacologic approaches."
Jack Rubinstein, MD, chief medical officer of TRPV Pharmaceuticals, UC researcher and professor of internal medicine at the UC College of Medicine. Photo/Andrew Higley/UC Marketing + Brand
According to the AHA, over 6 million Americans currently struggle with heart failure, with over 1 million new cases diagnosed annually in adults aged 55 and older.
The TRPV channel family that the Rubinstein laboratory is targeting, was first identified in 1997 by David Julius, PhD. His groundbreaking work with capsaicin compounds and the body's receptors earned him the Nobel Prize in 2021 for TRPV1. Rubinstein has dedicated nearly two decades of study related to cardiovascular disease and has been focusing on the TRPV2 variant of this channel for over a decade.
“So, we’re in good company working with Nobel Prize laureates as we develop a derivative of probenecid for heart patients,” Sexton said. “This breakthrough discovery not only offers hope for improved cardiovascular treatments but also holds the potential to become the prescribed standard of care to save countless lives.”
TRPV Pharmaceuticals is raising its A-Round funding to support ongoing studies and the development of TRPV2 intravenous formulation and oral solid of the drug, probenecid.
The next phase typical in biopharmaceutical product development involves conducting clinical trials tailored to validate efficacy within the cardiovascular domain, focusing mainly on acute-to-compensated heart failure or heart failure with reduced ejection fraction.
Geoffrey Pinski, assistant vice president of Technology Transfer located within the UC 1819 Innovation Hub said, “We solidified intellectual property protection and now the licensing enables the development of this future treatment.”
Pinski and his team’s successful acquisition of patents in the United States and other significant global economic regions represents a pivotal advancement toward the commercialization and realization of this promising treatment.
Featured image at top: Jack Rubinstein, MD, UC professor of internal medicine, UC College of Medicine. Photo/Andrew Higley/UC Marketing + Brand
Innovation Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.Replace with your text
Related Stories
Bono, Chris Tucker Visit UC To Discuss Africa
December 5, 2002
U2's Bono and comedian-actor Chris Tucker led a delegation from the DATA organization who came to UC to talk about potentially catastrophic problems in Africa.
New Year's Help for Those Looking to Kick the Habit
December 20, 2002
Quitting smoking consistently ranks among the top three resolutions made by New Year's resolvers each year.
E-BRIEF: Let's Toast to a Healthier 2003
January 8, 2003
The New Year often means a new health kick: Vows to tone up and trim down, and maybe going to the doctor and getting ourselves as regularly "maintenanced" as we do our cars. So, this week's University of Cincinnati e-briefing examines the health concerns of the young and old, and what you should be doing to preserve your good health.
Today's ML King Events: One On, One Off
January 8, 2003
A memorial march, presentations, poetry and dance will pay tribute to the slain civil rights leader.
UC Named Lead Organization for OSHA Training Consortium
January 13, 2003
UC Continuing Medical Education (CME) has been selected as the lead organization for the Occupational Safety and Health Administration (OSHA) Great Lakes Training Consortium by the U.S. Department of Labor.
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 13, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 14, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 20, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 21, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
PROFILE: Cincinnatus Scholar Has Connections
February 2, 2003
Maribeth Mincey is one of 370 student volunteers assisting the Feb. 15 Cincinnatus Scholarship competition. This UC freshman is following in her father's footsteps as she enters UC, but through the Connections program, she's building a pathway of her own to a career in medicine.